芪阳玉阴颗粒改善高血压心肌重构的线粒体功能障碍
本研究结合转录组分析、网络药理学与体内外实验,探讨芪阳玉阴颗粒(QYYYG)治疗高血压心肌重构的机制。转录组提示线粒体功能障碍是关键病理改变,QYYYG可通过上调SIRT1表达增强线粒体生物合成,修复线粒体功能障碍,从而改善高血压心肌重构。
要点
- QYYYG可能通过上调SIRT1表达增强线粒体生物合成。
- 线粒体功能障碍是高血压小鼠心肌的关键病理改变。
- 体内外实验均显示QYYYG改善心肌重构和线粒体功能。
核心结论
- QYYYG可能通过上调SIRT1表达增强线粒体生物合成,改善高血压心肌重构的线粒体功能障碍。
研究设计与样本
- 研究分析NCBI GEO公共平台转录组数据及本研究的转录组数据,结合网络药理学预测靶点,并采用分子对接和分子动力学模拟分析结合。
- 体内实验采用Ang Ⅱ诱导的高血压小鼠模型评估QYYYG对心肌重构和线粒体功能障碍的作用。
- 体外实验构建Ang Ⅱ诱导的H9c2细胞心肌重构模型,评估QYYYG对心肌重构和线粒体功能障碍的影响。
主要发现
- 转录组分析提示线粒体功能障碍是高血压小鼠心肌组织的关键病理改变。
- 网络药理学预测SIRT1是QYYYG治疗高血压心肌重构的重要潜在靶点,几乎所有活性成分尤其是槲皮素与SIRT1具有良好结合亲和力。
- 体内实验证明QYYYG对Ang Ⅱ处理小鼠的高血压心肌重构有良好疗效,改善线粒体质量和数量,并增加心肌组织SIRT1水平。
- 体外实验显示QYYYG改善Ang Ⅱ处理的H9c2细胞心肌重构和线粒体功能障碍,上调SIRT1表达并增强线粒体生物合成。
临床怎么用
- 对于高血压心肌重构患者,QYYYG可能通过调控SIRT1/线粒体生物合成通路发挥心脏保护作用。
- 临床可结合线粒体功能相关指标评估QYYYG的疗效,但需进一步临床研究验证。
局限性
- 研究主要为临床前实验,尚缺乏临床随机对照试验验证QYYYG在高血压心肌重构患者中的疗效和安全性。
- QYYYG调控SIRT1和线粒体生物合成的具体分子机制仍需深入探究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Clinical studies have found that Qianyang Yuyin granule (QYYYG), a kind of oral Chinese patent medicine, had definite clinical effect for hypertensive myocardial remodeling. However, the potential mechanism is not entirely clear. AIM OF THE STUDY: The purpose of this research was to explore the underlying mechanism QYYYG on the treatment of hypertensive myocardial remodeling. MATERIALS AND METHODS: Analysis the transcriptome data from the NCBI public platform GEO database and our study to explore the key pathological change of myocardial tissues in hypertensive mice and the main pathway of QYYYG in treating hypertensive myocardial remodeling. Network pharmacological analysis was used to predict the potential target of QYYYG. The molecular docking and molecular dynamics simulation was used for molecular binding analysis of specific compounds and target proteins. In the experiment in vivo, the effect of QYYYG on hypertensive myocardial remodeling and myocardial mitochondrial dysfunction in hypertensive mice caused by Ang Ⅱ was estimated. In the experiment in vitro, the Ang Ⅱ-induced myocardial remodeling model in H9c2 cells was constructed, and the effect of QYYYG on ameliorating myocardial remodeling and mitochondrial dysfunction was evaluated. RESULTS: Transcriptome analysis suggested that mitochondrial dysfunction was a key pathological change of myocardial tissues in hypertensive mice, and QYYYG could improve hypertensive myocardial remodeling through enhancing mitochondrial biogenesis to repair myocardial mitochondrial dysfunction. Network pharmacological analysis predicted that SIRT1 was an important potential target of QYYYG in treating hypertensive myocardial remodeling, and basically all the active components, especially quercetin, had a great binding affinity with SIRT1. Experiments in vivo proved that QYYYG had great efficacy hypertensive myocardial remodeling in Ang Ⅱ-treated mice. It was found that QYYYG improved the quality and quantity of mitochondria, and increased SIRT1 levels in myocardial tissue of Ang Ⅱ-treated mice. In Ang Ⅱ-treated H9c2 cells, with intervention of QYYYG, myocardial remodeling and myocardial mitochondrial dysfunction was ameliorated. In addition, QYYYG up-regulated SIRT1 expression and enhanced mitochondrial biogenesis in Ang Ⅱ-treated H9c2 cells. CONCLUSION: This study suggested that mitochondrial dysfunction was an important pathological change of myocardial tissues in hypertensive mice. QYYYG might ameliorate the mitochondrial dysfunction of hypertensive myocardial remodeling through up-regulating SIRT1 expression to enhance the mitochondrial biogenesis.
引用
- Zheng Y, Fang Y, Luo Y, et al. Qianyang yuyin granule ameliorates mitochondrial dysfunction of hypertensive myocardial remodeling. J Ethnopharmacol. 2024. PMID: 39047880. doi:10.1016/j.jep.2024.118610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。